Omid Moghadam is the founder and CEO of Namida Lab, a revenue-stage diagnostics company specializing in developing and commercializing liquid biopsy tests for early cancer detection. Namidas first product, Auria, is a direct-to-consumer proteomic test allowing women to take charge of their breast health. Hes an inventor, entrepreneur, venture investor, and educator. He specializes in launching new ventures with social impact in health and technology. Moghadam has inventions in medical imaging, cryptography, microprocessor design, medical devices, diagnostics, digital photography, data-science and communications. Hes the past founder or co-founder of nine companies in Healthcare IT, genomics, diagnostics, and medical imaging, and has held executive positions at Intel, Eastman Kodak, and CTG-AMS Corporations. He formerly served on the advisory boards of Robert Wood Johnson Foundation, Childrens Hospital Boston, Abbott Corporation, and California Healthcare Foundation and has held academic positions at Harvard Medical School department of biomedical informatics, as well as an Executive-In-Residence position at UCLA.
Track Chair: Sean Khozin, CancerLinQ